OraTech Pharmaceuticals Inc.: A New Standalone Company Focused on Oral Drug Delivery
In a recent business move, Oramed Pharmaceuticals Inc. announced the formation of a new standalone company named OraTech Pharmaceuticals Inc. This new entity will focus on the development and commercialization of oral drug delivery systems using Oramed’s proprietary POD™ (Protein Oral Delivery) technology. This strategic investment in OraTech signifies Oramed’s commitment to advancing oral protein therapeutics, as the technology has shown potential in delivering insulin and other peptides and proteins directly to the systemic circulation through the mouth.
Investment and Global Marketing Rights
As part of the deal, Oramed shareholders will receive the right to a direct stake in OraTech. The new company is expected to go public on the Nasdaq stock exchange, offering an opportunity for investors to capitalize on the potential growth of the oral drug delivery market. OraTech will have exclusive global marketing rights to Oramed’s POD™ technology, allowing it to collaborate with pharmaceutical and biotech companies worldwide to develop and commercialize oral protein drugs in various therapeutic areas.
Advanced Manufacturing Capabilities
OraTech will be equipped with advanced manufacturing capabilities to produce these oral protein drugs at scale. The new company will establish a state-of-the-art manufacturing facility, enabling it to produce clinical and commercial batches of oral protein drugs using Oramed’s POD™ technology. This in-house manufacturing capability will provide OraTech with a competitive edge, as it can ensure the quality and consistency of its products while reducing dependence on external manufacturers and minimizing supply chain risks.
Impact on Individuals
For individuals with diabetes or other chronic conditions requiring protein or peptide-based medications, OraTech’s oral drug delivery systems could offer a more convenient and less invasive alternative to existing injection therapies. The ability to take these medications orally, rather than through injections, could lead to improved patient compliance and quality of life. Additionally, for those who fear needles or have difficulty administering injections, oral protein drugs could provide a more accessible and practical solution.
Impact on the World
The development and commercialization of oral protein drugs through OraTech could significantly impact the global healthcare landscape. According to a report by Grand View Research, the oral drug delivery market is expected to reach $353.15 billion by 2027, growing at a CAGR of 10.1% from 2020 to 2027. OraTech, with its exclusive global marketing rights to Oramed’s POD™ technology, is well-positioned to capitalize on this growth. Additionally, the convenience and accessibility of oral protein drugs could lead to better patient outcomes and reduced healthcare costs by decreasing the need for expensive injectable therapies and associated healthcare resources.
Conclusion
The formation of OraTech Pharmaceuticals Inc. represents an exciting step forward in the field of oral drug delivery, with the potential to revolutionize the way we administer protein and peptide-based medications. With Oramed’s proprietary POD™ technology, advanced manufacturing capabilities, and global marketing rights, OraTech is poised to make a significant impact on the healthcare industry and improve the lives of individuals with chronic conditions requiring protein or peptide-based therapies. As the oral drug delivery market continues to grow, OraTech is well-positioned to capitalize on this trend and drive innovation in this field.
- Oramed forms new standalone company, OraTech Pharmaceuticals Inc., focused on oral drug delivery using POD™ technology
- Oramed shareholders to receive a direct stake in OraTech and exclusive global marketing rights to POD™ technology
- Advanced manufacturing capabilities to produce oral protein drugs at scale
- Potential for more convenient and less invasive alternative to injectable therapies for individuals with chronic conditions
- Global oral drug delivery market expected to reach $353.15 billion by 2027
